%20M.webp)
_D.webp)
Punto Health, the British startup building an AI-driven platform for early detection and personalised support in dementia and cognitive care, has raised a £2m seed round co-led by Shilling VC and Plus Partners, with participation from Exceptional Ventures, Heartfelt, Fondo Bolsa Social, and ABAC Nest. The funding will accelerate product development and commercial expansion across the UK and Spain.
Founded in 2023 in London by engineers Anna Muñoz-Farré and Jack Eckersley, Punto Health is tackling one of the biggest and fastest-growing health challenges. By 2030, 78 million people are expected to be living with dementia, and one in two people will be affected either as a patient or carer at some point in their lives.
Punto Health has created what it describes as the operating system for dementia care: a multilingual digital platform that connects patients, carers, and clinicians across three core products.
Their AI-powered, speech-based digital test PuntoTest assesses cognitive impairment in adults. It supports healthcare professionals and researchers with objective, quantifiable metrics of cognitive function, assisting with early detection, remote monitoring, and clinical triage at scale.
Their companion app PuntoCare is for patients, carers, and active seniors, providing personalised daily care plans, including cognitive stimulation exercises, physical activity, nutrition advice, symptom tracking and lifestyle recommendations. Users can access an AI-based virtual companion that only responds with clinically validated information, providing trustworthy answers and support, without replacing professional care.
And PuntoClinic, their clinician-facing dashboard, aggregates patient-reported outcomes and biomarker data to support more personalised, data-driven decision-making, as well as streamlining research activities such as clinical trial pre-screening and participant monitoring.
Punto Health’s platform is co-designed and clinically validated in partnership with Ace Alzheimer Center Barcelona, one of Europe’s foremost centres for dementia diagnosis and research. Together, they are building a cutting-edge digital biomarker that can detect changes in cognitive status through speech analysis, giving clinicians a more detailed view of disease progression across multiple cognitive domains.
In Spain, PuntoTest has already been tested in a rapid cognitive screening programme, alongside Ace Alzheimer Center and Nutricia, across ten pharmacies in Barcelona, and involving more than 1,500 participants aged 50 and above.
Meanwhile, PuntoCare is being piloted at North London NHS FT, NHS Oxleas FT, Hospital del Mar in Barcelona and Hospital General de Granollers, amongst others. It now supports more than 200 users, aged 60 to 90, who have completed over 30,000 activities, and more than two-thirds report feeling better managing their day-to-day.
Punto Health’s progress is notable in a space marked by two persistent funding gaps. Dementia remains significantly underfunded globally, despite its growing societal burden. At the same time, female-founded startups, especially in AI and software, receive only a small share of venture investment. For a disease that disproportionately affects women, both as patients and as unpaid carers, this double inequity has real consequences for the pace of progress.
Punto Health has been already awarded with the NN Social Innovation Award 2025 powered by Rubio Impact Ventures and NN Group and is a finalist in VIII Edición de los Premios Discapnet by Fundación ONCE. They have been also selected to be part of remarkable programs such as the AD Moonshot by Startup Health and the Alzheimer’s Drug Discovery Foundation and the AI-First Google Accelerator 2025.
The seed round builds on a $£630,000 pre-seed investment and a growing list of international recognitions that underscore Punto Health’s momentum as a leading innovator in dementia and cognitive-health technology.
